Denali Therapeutics

Yahoo Finance • 19 days ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Tividenofusp alfa treatment showed reduction and normalization in key disease biomarkers, stabilization or improvement in clinical endpoints including adaptive behavior, cognition and hearing, and normalization of liver volume Most common... Full story

Yahoo Finance • 20 days ago

3 Biotech Stocks With Major 2026 Catalysts

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns about potential high tariffs initially hurt the industry, sentiment among investors rebounded sharply, powering a no... Full story

Yahoo Finance • last month

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $1... Full story

Yahoo Finance • last month

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and, in lieu of common stock to certain i... Full story

Yahoo Finance • last month

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • last month

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future... Full story

Yahoo Finance • 2 months ago

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth

INDIANAPOLIS, Nov. 6, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry... Full story

Yahoo Finance • 2 months ago

Denali Therapeutics Announces Board and Executive Leadership Updates

Denali Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has bee... Full story

Yahoo Finance • 2 months ago

DNLI January 2026 Options Begin Trading

Investors in Denali Therapeutics Inc (Symbol: DNLI) saw new options begin trading today, for the January 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 72 days... Full story

Yahoo Finance • 3 months ago

First Week of June 2026 Options Trading For Denali Therapeutics (DNLI)

Investors in Denali Therapeutics Inc (Symbol: DNLI) saw new options become available this week, for the June 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 244... Full story

Yahoo Finance • 3 months ago

Denali Therapeutics gets FDA review extension for tividenofusp alfa

[Double exposure microscope Young woman scientific using equipment for research. Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology] jittawit.21/iStock via Getty Images * Denali Therapeutics (NASDA... Full story

Yahoo Finance • 3 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application... Full story

Yahoo Finance • 5 months ago

Denali therapeutics' Ho Carole sells $52k in stock

Denali Therapeutics Inc. (NASDAQ:DNLI), a $2.1 billion market cap biotech company currently trading at $14.46, saw its Chief Medical Officer Carole Ho sell 3,743 shares of common stock on August 12 and 13, 2025, for approximately $51,683.... Full story

Yahoo Finance • 5 months ago

Denali Therapeutics COFO Schuth sells $39884 in stock

Alexander O. Schuth, Chief Financial Officer and Secretary of Denali Therapeutics Inc. (NASDAQ:DNLI), sold 2,937 shares of the company’s common stock on August 12, 2025. The shares were sold at a weighted average price ranging from $13.35... Full story

Yahoo Finance • 5 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launchDNL126 accelerated approval path for Sanfilippo syndrome Type A aligned... Full story

Yahoo Finance • 6 months ago

William Blair reiterates Outperform rating on Denali stock after BLA acceptance

Investing.com - William Blair has reiterated its Outperform rating on Denali Therapeutics Inc. (NASDAQ:DNLI) following the Biologics License Application (BLA) acceptance and priority review for the company’s Hunter syndrome treatment. Th... Full story

Yahoo Finance • 8 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. “The completion of our... Full story

Yahoo Finance • 10 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Rolling submission of BLA initiated for tividenofusp alfa; preparations ongoing for potential U.S. commercial launch in late 2025 or early 2026Alignment through recent interactions with CDER on path to accelerated approval and conversion t... Full story

Yahoo Finance • 11 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. “In 2024,... Full story

Yahoo Finance • 11 months ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behavior Long-term safety data with median follow-u... Full story